Table 2

Outcome of therapy in elderly patients with AML

Control groupG-PBSC groupP
Complete remission rates    
    After the first induction, n/N 8/28 19/30 .006 
    After the second induction, n/N 12/28 24/30 .006 
    Patients >70 y, n/N 1/8 13/14 .0003 
    Patients <70 y, n/N 11/20 11/16 .4 
    In high-risk category, n/N 4/13 7/12 .23 
    In standard-risk category, n/N 8/15 17/18 .01 
Disease resistance, n/N 11/28 3/30 .01 
Early death rate, n/N 4/28 2/30 .69 
Median time of ANC > 0.5 × 109/L, d    
    After the first induction 16 11 .02 
    After the post-remission 12.5 10 .06 
Median time of platelet count > 30 × 109/L, d    
    After the first induction 20 14.5 .02 
    After the post-remission 17 14 .06 
Severe infection    
    After the first induction, n/N 16/28 8/30 .02 
    After the post-remission, n/N 4/12 5/24 .44 
Control groupG-PBSC groupP
Complete remission rates    
    After the first induction, n/N 8/28 19/30 .006 
    After the second induction, n/N 12/28 24/30 .006 
    Patients >70 y, n/N 1/8 13/14 .0003 
    Patients <70 y, n/N 11/20 11/16 .4 
    In high-risk category, n/N 4/13 7/12 .23 
    In standard-risk category, n/N 8/15 17/18 .01 
Disease resistance, n/N 11/28 3/30 .01 
Early death rate, n/N 4/28 2/30 .69 
Median time of ANC > 0.5 × 109/L, d    
    After the first induction 16 11 .02 
    After the post-remission 12.5 10 .06 
Median time of platelet count > 30 × 109/L, d    
    After the first induction 20 14.5 .02 
    After the post-remission 17 14 .06 
Severe infection    
    After the first induction, n/N 16/28 8/30 .02 
    After the post-remission, n/N 4/12 5/24 .44 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal